<DOC>
	<DOCNO>NCT00644371</DOCNO>
	<brief_summary>To evaluate use ibritumomab tiuxetan ( Zevalin ) part non myeloablative conditioning melphalan , fludarabine thiotepa patient submit allogeneic transplantation haematopoietic stem cell family donor 's peripheral blood .</brief_summary>
	<brief_title>Allogenic Stem Cell Transplantation ( SCT ) With Non-myeloablative Conditioning Patients With Relapse Non-Hodgkin 's Lymphoma ( NHL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Written inform consent 2 . Histologically confirm Bcell lymphoma follow subtypes : LBCDL Grade 3b follicular lymphoma Mantlecell lymphoma Transformed Bcell lymphoma Burkitt lymphoma patient eligible conventional allogeneic transplant 3 . Highrisk Bcell CD20+ lymphoma define Having attain less PR two chemotherapy line Posttransplantation relapse Presence disease detect metabolic approach ( PET/CT else CT+PET ) either autologous transplantation Inability collect enough stem cell autologous transplantation 4 . Stable disease time transplantation 5 . Age 18 65 6 . Performance status ( ECOG ) ≤ 2 7 . Normal suitable pulmonary function ( DLCO ≥ 30 % ) 8 . Left ventricular ejection fraction ( LVEF ) determine ventriculography echocardiogram ≥ 40 % 9 . Normal hepatic renal function , creatinine ≤ 2 mg/dl Bi ≤ 1.5 mg/dl , alkaline phosphatase ≤ 2.5 x UNL ; AST , ALT ≤ 2.5 x UNL ( ≤ 5 x UNL hepatic infiltration ) 1 . Prior treatment radiopharmaceutical agent 2 . HIVassociated lymphoma 3 . Presence human antimouse antibody ( HAMA ) antichimeric antibody ( HACA ) 4 . Patient 's inability follow protocol 5 . Hypersensitivity 90Yitritumomab tiuxetan 6 . Presence severe pathology preclude chemotherapeutic treatment 7 . Pregnant woman pregnancy risk due inappropriate contraceptive measure 8 . Breastfeeding woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Allogeneic</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>GELTAMO</keyword>
	<keyword>Z-RIC</keyword>
</DOC>